David Bogoslaw

Permanent Capital sees its GTM assistance as key differentiator

The Chicago-based firm closed on $200m for its sophomore fund, with LPs including state retirement funds, funds of funds, endowments and large family offices.

Meet the LP: Hamilton Lane

While the firm's venture capital and growth equity team favors re-ups with existing fund relationships, it spends a disproportionate amount of time with new managers to learn what's emerging in the market.

How AI is enabling the next wave of healthtech

Growing familiarity with AI and machine learning is helping break down investors’ natural resistance to category-defying technologies.

Learning from exceptional people drives 645 Ventures' newest partner

Parul Singh is targeting the gap between what AI agents can do and how much developers trust them to do it unsupervised.

Summit Peak Ventures closes on $58.6m for Fund IV, targeting $150m

LPs in the Fort Worth-based VC firm’s previous funds include the Massachusetts Institute of Technology Basic Retirement Plan, Crown Cork & Seal Company Retirement Plan and The Miles Foundation.

Filling a funding gap in UK bioconvergence

How a small accelerator born at the Francis Crick Institute is helping UK start-ups find investors who speak their language

Better epilepsy monitoring gets healthy dose of VC

A wearable sensor and machine learning are giving epilepsy patients weeks of seizure monitoring where days used to be the limit.

Commercialization brings hurdles for bioconvergence investing

Bioconvergence products blur the lines between drugs, devices and software – and with them, the rules for getting to market.

Investing in the age of bioconvergence

The burgeoning space that mixes biology, engineering, computer science and AI has already delivered some big exits.

AI is 'next tool in the toolkit' for bioconvergence

The reach of artificial intelligence now spans the entire drug pipeline, prompting Big Pharma to reconsider outsourcing innovation.